Industrias
Packaging
Todos los análisis de Packaging — 8 análisis.
38/100
70Buffett
AptarGroup: Pharma Carries the Profit, the Price Leaves No Cushion
AptarGroup supplies regulated drug-delivery components and consumer dispensing systems, and the split defines the equity: Pharma was 46% of 2025 sales but 69% of reportable-segment adjusted EBITDA. Q2 2026 makes the argument concrete. Standard Pharma core sales grew just 1% while management's figure excluding emergency-medicine destocking was about 8%, and Pharma adjusted EBITDA margin fell 180 basis points to 33.6%; Emergent's 16% first-half naloxone decline suggests part of the lost revenue has re-based structurally, so this report normalizes Pharma core growth at 5% to 6% rather than capitalizing 8%. Rating Hold: at $134.72 a sum-of-the-parts implies about 13.7 times Pharma EBITDA while the conservative case is worth roughly $134, leaving no margin of safety above the $100 to $107 ideal buy zone.
35/100
67Buffett
SCHOTT Pharma: A GLP-1 Boom Priced by the Dose, Not the Drug, and a Capacity Bill That Has Yet to Prove Its Return
SCHOTT Pharma supplies the glass and polymer syringes, cartridges, vials and ampoules that hold injectable medicines, earning a manufacturing price per container rather than a share of the price of the drug inside it. That distinction explains the gap the market misread: management puts injectable-drug market growth at 9 to 10% in 2025 against 1 to 2% for primary packaging, and although high-value sterile formats reached 57% of fiscal 2025 revenue and July guidance was lifted to 5 to 6% growth and a 27 to 28% EBITDA margin, polymer-syringe underutilisation, EUR 140 to 160 million of annual capital expenditure and SCHOTT AG's 77% control keep free cash flow and minority influence thin. Rating Hold: the recovery is credible and the balance sheet is sound, but at 22.15 EUR the shares yield under 2% on consensus free cash flow and sit above the 16 to 18 EUR ideal buy zone.
39/100
International Paper Deep Value Investment Research
International Paper is a global fiber-based packaging company focused on containerboard and corrugated boxes, with a cyclical, asset-heavy model whose moat comes more from regional scale and execution than from brand. The business is understandable but average in quality; after a major 2025 acquisition, it quickly recorded about $2.5 billion of impairment and diluted per-share economics, while the current price of about $33.47 sits near the lower end of fair value with an insufficient margin of safety. Report rating Watch: an understandable but restructuring-heavy industrial asset that is better kept on the watchlist, with an ideal buy range of $24 to $29.
39/100
Smurfit WestRock: A Long-Term Business Owner's Investment Analysis
Global leader in paper-based packaging formed by the merger of Smurfit Kappa and WestRock. At about $41 the stock sits between a conservative intrinsic-value band of $32-38 and a base-case band of $45-58, leaving a thin margin of safety; ideal entry is $32-36. Rating Watch: a quality but unproven integration story that needs a cheaper entry or clearer proof of North America execution.
40/100
76Buffett
Packaging Corporation of America Deep Value Investment Analysis
The third-largest containerboard and corrugated packaging producer in North America, with an easy-to-understand business, solid cash flow, and rational management; but at the current price of about $218, the TTM P/E is around 26.2x and the owner earnings yield is just above 4%, leaving insufficient margin of safety, with fair value at $170-210.
44/100
76Buffett
West Pharmaceutical Services In-Depth Value Research Report
West makes high-validation-barrier packaging for injectable drugs—elastomer stoppers, prefilled components and the like—with a deep moat, net cash, and solid cash flow, but at $321.8 it trades at about 44x Owner Earnings, leaving little visible margin of safety; the ideal buy range is $180–240. Risks include a single customer at 15.8% of revenue, the inventory cycle, and management succession.
41/100
78Buffett
Avery Dennison Pressure-Sensitive Labels & RFID Deep Dive
AVY is the global leader in pressure-sensitive label materials with RFID/digital identity as an incremental driver, TTM FCF $873 million, P/FCF 14x, EV/EBITDA 10.9x; at the current $159.66 it sits in the gap between the conservative and fair-value ranges — reasonably acceptable rather than clearly undervalued.
35/100
Amcor: Packaging Platform and M&A Integration Study
Amcor is a global leader in flexible and rigid packaging; after the Berry acquisition net debt sits at 14.266 billion and net leverage at 4.2x, on the high side. At the current 38.38 dollars, forward adjusted PE is just 9.6x with a 6.7% dividend yield, but if integration falls short, returns get squeezed back to mediocre. Rating Watch: a defensible, cash-generative packaging platform whose payoff hinges on Berry synergies landing and deleveraging executing.